Compare DLPN & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | NXL |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 18.6M |
| IPO Year | 2008 | N/A |
| Metric | DLPN | NXL |
|---|---|---|
| Price | $1.72 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 41.2K | ★ 384.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,684,984.00 | N/A |
| Revenue This Year | $10.62 | $38.28 |
| Revenue Next Year | $13.78 | $185.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $0.75 | $0.37 |
| 52 Week High | $1.88 | $2.80 |
| Indicator | DLPN | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 61.33 | 47.84 |
| Support Level | $1.46 | $0.37 |
| Resistance Level | $1.73 | $0.69 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 94.64 | 51.97 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.